Evaluation of a Symmetric Dimethylarginine in Serum of Type 2 Diabetic Patients.

Abstract

AbstractBackground: Type 2 diabetes mellitus (DM2) is suddenly increasing in incidence, and is associated with increase risk for cardiovascular disease, because of the macrovascular and microvascular injury. Although the main physiological abnormalities are insulin resistance and impaired insulin secretion, the specific determinants of these metabolic defects remain uncertain. The experimental evidences suggest that inflammation may play an intermediary role in pathogenesis, there by linking diabetes with a number of commonly coexisting conditions thought to originate through inflammatory mechanisms. Serum asymmetric dimethylarginine (ADMA) level is biomarker of endothelial dysfunction and cardiovascular disease. Aim: The aim of this study was to evaluate levels of ADMA, and its association with the complications of type 2 diabetic patients.Materials and Methods: The ADMA serum levels were measured in 75 of type2 diabetic patients and 75 healthy control subjects by using high performance liquid chromatography (HPLC).Results: A statistically significant differences was found in serum levels of ADMA between diabetic and healthy control groups (p>0.001). Serum levels of ADMA correlated significantly with the levels of (HbA1c(% in type 2 diabetic patients.Conclusion: These results suggest that serum ADMA levels directly contribute to the complications of cardiovascular disease in type 2 diabetic patients.Key Words: type 2 diabetes mellitus, a symmetric dimethylarginine, (HbA1c (%, lipid profile.